secwatch.observer — SEC 8-K summary
======================================

Issuer:     First Tracks Biotherapeutics, Inc. (TRAX)
CIK:        0002091349
Form:       8-K
Filed at:   2026-08-12T20:19:20+00:00
Accession:  0001193125-26-346908
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First Tracks Q2 net loss $33.4M, cash $168M; ANB033 Fast Track, Cohort 1 data Q4
--------------------------------------------------------------------------------

- Q2 2026 net loss $33.4M ($0.95/share) vs $42.4M ($1.47) year-ago; R&D spend $25.6M.
- FDA granted Fast Track designation for ANB033 in celiac disease; Cohort 1 (n=30) fully enrolled, data Q4 2026.
- Cohort 2 expanded to up to 40 patients; top-line data expected Q1 2027; EoE Phase 1b data Q3 2027.
- Cash and investments $168.0M as of June 30, 2026; runway into Q2 2028.
- Planning Phase 2 trials in two additional indications in H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/0001193125-26-346908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/trax-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer